International expert consensus on the management of bleeding during VATS lung surgery
Lunxu Liu(Sichuan University), Alessandro Brunelli(Marche Polytechnic University), Jiandong Mei(Sichuan University), Yuming Zhu(Chinese Academy of Medical Sciences & Peking Union Medical College), Jian Hu(First Affiliated Hospital Zhejiang University), Gening Jiang(Tongji University), Xingyi Zhang(Roswell Park Comprehensive Cancer Center), Luca Bertolaccini, Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Serdar Evman(Roswell Park Comprehensive Cancer Center), Wentao Fang(Bristol-Myers Squibb (Germany)), Shidong Xu(Harbin Medical University), Yi‐Dan Lin(Sichuan University), Todd L. Demmy(Roswell Park Comprehensive Cancer Center), Deruo Liu(Roswell Park Comprehensive Cancer Center), Gregor J. Kocher(Roswell Park Comprehensive Cancer Center), Xiangning Fu(Tongji Hospital), Qinghua Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Ti Tong(Roswell Park Comprehensive Cancer Center), Javier Aragón(Roswell Park Comprehensive Cancer Center), Qiang Pu(Sichuan University), Liang Chen(Jiangsu Province Hospital), Qun Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaofei Li(Air Force Medical University), Chun Chen(Fujian Medical University), Zhu Zhang(Sichuan University), Xun Zhang(Harvard University), Yin Li(Third Affiliated Hospital of Sun Yat-sen University), Lin Ma(Sichuan University), Jie He(Chinese Academy of Medical Sciences & Peking Union Medical College), Lin Xu(First Affiliated Hospital Zhejiang University), Shanqing Li(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianhua Fu(Bristol-Myers Squibb (Germany)), Hui Li(State Key Laboratory of Natural Medicine), Jianxing He(Southern Medical University), Xiuyi Zhi(Roswell Park Comprehensive Cancer Center), Tiansheng Yan(Roswell Park Comprehensive Cancer Center), Zhentao Yu(Bristol-Myers Squibb (Germany)), Yunchao Huang(Kunming Medical University), Lanjun Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Lijie Tan(Fudan University), Qunyou Tan(Sichuan University), Weimin Mao(Bristol-Myers Squibb (Germany)), Zhongmin Jiang(Chinese People's Liberation Army), Yongyu Liu(Liaoning Cancer Hospital & Institute), Yang Liu(China National GeneBank), Qingquan Luo(Shanghai Jiao Tong University), Haiquan Chen(Fudan University Shanghai Cancer Center), Guowei Che(Sichuan University)
Cited by 42
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Cancer incidence and mortality in China, 2022
|Journal of the National Cancer Center|2024|2k
Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing
|Nature Medicine|2018|1.8k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Cancer incidence and mortality in China, 2016
|Journal of the National Cancer Center|2022|1.6k